drugset / Trial / NCT03618316

Effect of Cimetidine on the PK of Imeglimin

NCT03618316

Phase 1 Completed 16 enrolled Poxel SA
NaSingle-groupOpen-labelOther

Summary

The trial is an open-label assessment of the interaction of imeglimin with cimetidine. Up to 16 healthy men and women will receive a single oral dose of 1,500 mg imeglimin alone followed by a second dose of imeglimin during repeated doses of 400 mg cimetidine taken twice daily for 6 days.

Timeline

Start
2018-06-19
Primary completion
2018-07-21
Completion
2018-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Cimetidine Small molecule 400 mg
Subject Imeglimin Small molecule 1500 mg Oral

Indications

No indication recorded.